Idarucizumab Improves Outcome in Murine Brain Hemorrhage Related to Dabigatran

Annals of Neurology

Volumn 78, Issue 1, 2015, Pages 137-141

  Na, Shin Young ^a   Mracsko, Eva ^a   Van Ryn, Joanne ^b   Veltkamp, Roland ^a,c  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DABIGATRAN ETEXILATE; HEMOGLOBIN; IDARUCIZUMAB; ANTICOAGULANT AGENT; ANTITHROMBIN; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; DABIGATRAN; MONOCLONAL ANTIBODY; WARFARIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTICLE; BLEEDING TIME; BLOOD VOLUME; BRAIN HEMATOMA; CONTROLLED STUDY; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; THROMBIN TIME; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD CLOTTING; BRAIN; BRAIN HEMORRHAGE; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; HEMATOMA; PATHOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTICOAGULANTS; ANTITHROMBINS; BENZIMIDAZOLES; BETA-ALANINE; BLEEDING TIME; BLOOD COAGULATION; BRAIN; CEREBRAL HEMORRHAGE; DISEASE MODELS, ANIMAL; HEMATOMA; MICE; THROMBIN TIME; WARFARIN;

EID: 84932638493     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24421     Document Type: Article

References (19)

1. European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery;, Camm AJ, Kirchhof P, Lip GY, et al., Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-2429.
2. Camm AJ, Lip GY, De Caterina R, et al., 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation-developed with the special contribution of the European Heart Rhythm Association. Europace 2012; 14: 1385-1413.
3. Kernan WN, Ovbiagele B, Black HR, et al., Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014; 45: 2160-2236.
4. Hankey GJ,. Secondary stroke prevention. Lancet Neurol 2014; 13: 178-194.
5. Harper P, Young L, Merriman E,. Bleeding risk with dabigatran in the frail elderly. N Engl J Med 2012; 366: 864-866.
6. Veltkamp R, Rizos T, Horstmann S,. Intracerebral bleeding in patients on antithrombotic agents. Semin Thromb Hemost 2013; 39: 963-971.
7. Steiner T, Rosand J, Diringer M,. Intracerebral hemorrhage associated with oral anticoagulant therapy: current practices and unresolved questions. Stroke 2006; 37: 256-262.
8. Hart RG, Diener HC, Yang S, et al., Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke 2012; 43: 1511-1517.
9. Qureshi AI, Mendelow AD, Hanley DF,. Intracerebral haemorrhage. Lancet 2009; 373: 1632-1644.
10. Lauer A, Pfeilschifter W, Schaffer CB, et al., Intracerebral haemorrhage associated with antithrombotic treatment: translational insights from experimental studies. Lancet Neurol 2013; 12: 394-405.
11. van Ryn J, Schurer J, Kink-Eiband M, Clemens A,. Reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat-tail bleeding model and lack of effect on assays of coagulation. Anesthesiology 2014; 120: 1429-1440.
12. Zhou W, Schwarting S, Illanes S, et al., Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke 2011; 42: 3594-3599.
13. Zhou W, Zorn M, Nawroth P, et al., Hemostatic therapy in experimental intracerebral hemorrhage associated with rivaroxaban. Stroke 2013; 44: 771-778.
14. Schiele F, van Ryn J, Canada K, et al., A specific antidote for dabigatran: functional and structural characterization. Blood 2013; 121: 3554-3562.
15. Lu G, DeGuzman FR, Hollenbach SJ, et al., A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 2013; 19: 446-451.
16. Sun L, Zhou W, Ploen R, et al., Anticoagulation with dabigatran does not increase secondary intracerebral haemorrhage after thrombolysis in experimental cerebral ischaemia. Thromb Haemost 2013; 110: 153-161.
17. van Ryn J, Grottke O, Spronk H,. Measurement of dabigatran in standardly used clinical assays, whole blood viscoelastic coagulation, and thrombin generation assays. Clin Lab Med 2014; 34: 479-501.
18. Grottke O, Honickel M, van Ryn J, et al., A specific antidote to dabigatran reduces blood loss in dabigatran and trauma-induced bleeding in pigs. J Am Coll Cardiol 2014; 63: 60295-60303.
19. Rosenberg GA, Mun-Bryce S, Wesley M, Kornfeld M,. Collagenase-induced intracerebral hemorrhage in rats. Stroke 1990; 21: 801-807.